Dr. Dan Engle, a leading voice in psychedelic medicine, has been appointed by Mind Cure as a scientific advisor
As Mind Cure Health (CAN:MCUR) moves forward on its functional mushrooms operations, the Company is already positioning itself to expand into psychedelic drug R&D.
On October 1, 2020; Mind Cure announced the addition of Dr. Dan Engle as a scientific advisor. Dr. Engle has global stature in the fields of psychiatry and neurology. One of his areas of specialty is psychedelic drugs.
As a Mental Health Crisis rages around us, psychedelic drugs are being highly touted as the answer to this crisis. This Psychedelics Revolution is being driven by a confluence of voices.
Medical doctors, psychiatrists and other mental health specialists, and naturopaths have been leading this dialogue. But people from all walks of life are waking up to the medicinal potential of psychiatric drugs.
From high-profile media pundits to billionaire investors, people with no medical expertise are standing up to bang the drum for psychedelic drugs. Because the facts and data speak for themselves. And we are regularly seeing some of the same names pop up again and again.
Joe Rogan, who is also an outspoken proponent of functional mushrooms, is one of the media pundits who has been particularly vocal in alerting people to the potential of psychedelic drugs.
As far back as May 2015, Rogan was digging into the potential of psychedelics. And one of the experts he sought out for guidance was Dr. Dan Engle. Dr. Engle not only discussed the potential of psychedelic drug therapy, but also went into great detail on how these psychedelics were being integrated into psychotherapy – five years ago.
Another very prominent spokesman for psychedelic drugs is famed author/investor, Tim Ferriss. Ferriss was also an early advocate of psychedelics. In 2015, Ferriss was already actively promoting psychedelics-based medicine.
Engle’s own bio frames his expertise in this manner.
Dr. Dan Engle specializes in Psychiatry and Neurology, with a clinical practice that combines aspects of regenerative medicine, orthomolecular psychiatry, integrative spirituality and peak performance methods.
Currently, he is Medical Director of Kuya Institute for Transformational Medicine and consultant to Onnit Labs in Austin Texas, the True Rest Float Centers in Phoenix Arizona as well as several international healing centers using indigenous plant medicines of the Peruvian Amazon River basin.
A wealth of medical and naturopathic credentials. An international reputation. And Dr. Engle is bringing all of that to Mind Cure Health.
Mind Cure is a functional mushrooms/psychedelic medicine hybrid. Psychedelic Stock Watch has previously outlined this business model for investors.
The Company is leading with its functional mushrooms operations.
It’s Moonbeam product line of organic mushrooms already has its Health Canada product numbers (HPN). Ready to begin retail sales in what is a $23 billion dollar global market (according to Mordor Intelligence).
The market has given MCUR the thumbs-up for its initial focus on functional mushrooms.
Mind Cure began trading on September 21, 2020 at an IPO price of CAD$0.20. MCUR quickly took off, quadrupling to CAD$0.80 in its first week of trading. In a torrid week of trading, the Company outpaced industry heavyweights Compass Pathways (US:CMPS) and MindMed Inc (CAN:MMED / US:MMEDF).
Even as the Company has been getting traction with its functional mushrooms operations, management is now positioning Mind Cure to commence psychedelic drug R&D.
The appointment of Dan Engle is one of the first steps in this process.
After a 50-year deep freeze due to criminal Prohibition, psychedelic drugs are re-emerging into modern medicine. There is a great need here for both publicity and education.
Media icons like Joe Rogan and Tim Ferriss are aggressively publicizing the potential of psychedelic drugs to revolutionize the treatment of many mental health disorders, including depression, anxiety, addiction and PTSD.
Mental health experts like Dr. Dan Engle are explaining the virtues of psychedelic drugs to both potential consumers of these drugs and potential investors in the public companies seeking to develop them.
In the middle of this are the public companies themselves.
As Mind Cure forges ahead in this emerging industry, it has added not only a leading expert to help to advance its psychedelic drug research initiatives. It has also added one of the most respected voices in this field to its management team.
Big-name investors like Peter Thiel and Mike Novogratz have lent instant credibility to the psychedelic drug industry in capital markets.
Parallel to this, medical experts like Dr. Dan Engle are boosting the credibility and profile of psychedelic drugs within the medical profession.
In adding Dan Engle as a scientific advisor, Mind Cure has elevated its own profile in the competition to bring new psychedelic drug therapies to market.
DISCLOSURE: Mind Cure Health is a paid client of Psychedelic Stock Watch.
The content on Psychedelic Stock Watch is not personalized investment advice. Our employees strive to give smart, stimulating commentary, but are not licensed to address or give advice on individual investment situations. Nothing you receive from Psychedelic Stock Watch should be considered personal investment advice. Any investments recommended by Psychedelic Stock Watch should only be made after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. All investments carry risk of significant loss.
Please see full disclaimers at https://psychedelicstockwatch.com/ applicable to all content provided by PSW , wherever published or re-published: https://psychedelicstockwatch.com/statements-policies
Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This release/advertorial does not constitute an offer or solicitation to buy or sell any securities or individualized investment advice. This is a native advertisement, meaning it is an informational paid marketing piece. PsychedelicStockWatch.com (PSW) makes no recommendation that the securities of the issuers profiled or discussed on this website should be purchased, sold or held by viewers, whether or not viewers learn of the profiled issuers through our website or otherwise. Please review all investment decisions with a licensed investment advisor.
PSW receives media support and payments from the issuer or third-party companies that have contracted with the issuer ranging from approximately $25,000 to $150,000 to publish and/or distribute advertisements on behalf of the issuer. The issuer and/or third-party companies that have contracted with the issuer have not promised exclusivity to PSW and may hire additional publishers or advertisers on behalf of the issuer. PSW retains any excess sums after expenses as its compensation. PSW may be paid for services using cash, options, restricted shares, free-trading shares, or shares of other unrelated issuers, and thus PSW and its owners, operators and affiliates may benefit from any increase in the share prices of the profiled issuers.
PSW and/or its owners, operators and affiliates make no representations about their short-term or long-term investment horizons and may be selling shares of stock at the same time the profile (or other information) is being disseminated to potential investors; PSW is under no obligation to, and will not, advise any party when it or its affiliates decide to buy or sell shares. Investors must make all investment decisions based on their own judgment of the market and the particular securities.
This release/advertorial contains forward-looking statements that involve risks and uncertainties. This release/advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured issuer. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s),” “anticipate(s),” “plan(s),” “expect(s),” “project(s),” “will,” “make,” “told,” “could,” “might,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the issuer to differ materially from these indicated by such forward-looking statements. Certain statements contained herein are forward-looking statements as defined in Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the issuer or PSW or contained in this release/advertorial are not guarantees of future performance, and that the issuer’s actual results may differ materially from those set forth in the forward-looking statements. We undertake no obligation to update any statements made herein. Differences in results can be caused by various factors including, but not limited to, the issuer’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this release/advertorial contains “forward-looking statements.” Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. More information on the issuer that is the subject of this release/advertorial may be found at http://www.sec.gov where readers can review all public filings submitted by the issuer. PSW is not a certified financial analyst, investment advisor, broker/dealer, or licensed in the securities industry in any manner. The information in this advertorial is subjective opinion and may not be complete, accurate or current and was paid for by the issuer, creating a potential conflict of interest.
